Karyopharm Therapeutics Inc (KPTI) Shares Down Despite Recent Market Volatility

Karyopharm Therapeutics Inc (NASDAQ: KPTI)’s stock price has gone decline by -11.71 in comparison to its previous close of 1.58, however, the company has experienced a 0.36% increase in its stock price over the last five trading days. Zacks Investment Research reported 2024-02-29 that Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.43 per share a year ago.

Is It Worth Investing in Karyopharm Therapeutics Inc (NASDAQ: KPTI) Right Now?

KPTI has 36-month beta value of 0.05. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 1 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for KPTI is 105.69M, and currently, short sellers hold a 21.89% ratio of that float. The average trading volume of KPTI on April 03, 2024 was 1.77M shares.

KPTI’s Market Performance

KPTI stock saw an increase of 0.36% in the past week, with a monthly gain of 17.72% and a quarterly increase of 61.27%. The volatility ratio for the week is 10.44%, and the volatility levels for the last 30 days are 10.98% for Karyopharm Therapeutics Inc (KPTI). The simple moving average for the past 20 days is -2.40% for KPTI’s stock, with a 12.82% simple moving average for the past 200 days.

Analysts’ Opinion of KPTI

Many brokerage firms have already submitted their reports for KPTI stocks, with Piper Sandler repeating the rating for KPTI by listing it as a “Overweight.” The predicted price for KPTI in the upcoming period, according to Piper Sandler is $8 based on the research report published on January 19, 2023 of the previous year 2023.

RBC Capital Mkts, on the other hand, stated in their research note that they expect to see KPTI reach a price target of $10, previously predicting the price at $7. The rating they have provided for KPTI stocks is “Outperform” according to the report published on November 04th, 2022.

JP Morgan gave a rating of “Neutral” to KPTI, setting the target price at $8 in the report published on February 09th of the previous year.

KPTI Trading at 10.38% from the 50-Day Moving Average

After a stumble in the market that brought KPTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.36% of loss for the given period.

Volatility was left at 10.98%, however, over the last 30 days, the volatility rate increased by 10.44%, as shares surge +6.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +82.11% upper at present.

During the last 5 trading sessions, KPTI rose by +0.36%, which changed the moving average for the period of 200-days by -33.25% in comparison to the 20-day moving average, which settled at $1.4335. In addition, Karyopharm Therapeutics Inc saw 61.27% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at KPTI starting from Paulson Richard A., who sale 3,573 shares at the price of $1.30 back on Mar 05 ’24. After this action, Paulson Richard A. now owns 1,160,836 shares of Karyopharm Therapeutics Inc, valued at $4,645 using the latest closing price.

Paulson Richard A., the President and CEO of Karyopharm Therapeutics Inc, sale 19,374 shares at $1.20 during a trade that took place back on Mar 01 ’24, which means that Paulson Richard A. is holding 1,164,409 shares at $23,249 based on the most recent closing price.

Stock Fundamentals for KPTI

Current profitability levels for the company are sitting at:

  • -0.89 for the present operating margin
  • 0.97 for the gross margin

The net margin for Karyopharm Therapeutics Inc stands at -0.98. The total capital return value is set at -0.76.

Based on Karyopharm Therapeutics Inc (KPTI), the company’s capital structure generated 4.58 points at debt to capital in total, while cash flow to debt ratio is standing at -0.53. The debt to equity ratio resting at -1.28. The interest coverage ratio of the stock is -5.44.

Currently, EBITDA for the company is -129.01 million with net debt to EBITDA at -1.02. When we switch over and look at the enterprise to sales, we see a ratio of 1.95. The receivables turnover for the company is 5.42for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.37.

Conclusion

To put it simply, Karyopharm Therapeutics Inc (KPTI) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts